PRO-MR-RT Systematic Patient-reported Outcomes to Pelvic Online MRgRT

Background:

In 2018 the first patients worldwide were treated with the first 1.5 T MR-linac. The MR-linac is innovative technology in cancer treatment making precision radiotherapy possible, as it is a linear accelerator mounted on a ring around a 1.5-Tesla MRI Scanner combined with an online adaptive radiotherapy planning system. When the patient is positioned in the MR-linac it is possible to get real-time MR images with high soft tissue contrast, adapt the radiotherapy plan and subsequently irradiate at each treatment fraction. The improved visualization on the MR images makes it possible to see how the tumour and the organs around it changes and adapt the treatment plan every day. This opens up for a reduction of safety margins needed to insure target coverage and increased use of hypo- fractionation. Cancer patients will hopefully benefit from this with decreased treatment toxicity and increased local tumor control rates.

Today, computed tomography (CT)-guided intensity-modulated radiotherapy is standard treatment for patients with pelvic or abdominal tumors. However, the visualization of the tumor and surrounding tissue is poor due to low soft-tissue contrast in the cone-beam scans. When using MRI for online radiotherapy planning in pelvic and abdominal sites, the soft-tissue contrast will be high making it possible to improve contouring accuracy and reduce margins. The potential of the MR-linac lowering treatment toxicity can greatly impact survivorship and quality of life. This would particularly be beneficial for patients diagnosed with cancer in the pelvic region, like prostate cancer, having considerably high chances of survival.

The standard for toxicity monitoring in cancer clinical trials is the prospective clinician reporting of the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE). CTCAE grading, as well as patient-reported outcomes (PRO), is also part of the proposed standard assessment methodology for clinical evaluation of radiotherapy innovations like online MRgRT. Several studies have identified discrepancies between clinician and patient reporting within systemic treatment where clinicians appear to underreport the severity of treatment toxicity, compared to patient-reported severity. Therefore, patient self-reports are an important supplement to the evaluation of online MRgRT as in other oncological settings where they have been used as direct indicators of worsening, persistence or improvement of symptoms and general well-being. Furthermore, patient self-reports reduces the risk of unanticipated treatment toxicities being undetected.

Methods:

Study Design:

The study is a prospective single-arm longitudinal observational study including all prostate cancer patients treated with online MR-guided radiotherapy or CT-guided radiotherapy in the study period.

Participants:

Patients with prostate cancer referred for radiotherapy at Odense University Hospital in the time period 15.11.2020 - 01.07.2022 will be eligible for inclusion.

Data collection:

A patient pathway app, My Hospital, will be used for data collection. A PRO item set for patients with prostate cancer has been developed and tested in a pilot study (PRO-CTCAE and EORTC items). The item set will be used weekly during treatment and 4 weeks following to capture expected and unanticipated symptoms of acute treatment toxicity. During follow-up patients wll be asked to report 8, 12 and 24 weeks after radiotherapy completion. Other questionnaires will be used to measure quality of life (EORTC QLQ-C30+EORTC PR25), health-related quality of life (EQ-5D-5L), patient experience with ePRO (Patient Feedback Form) and patient experience with treatment on a 1.5 T Unity MR-linac (Patient Experience Questionnaire).

Data on clinician management of PROs will be drafted from the patient app My Hospital.